CA
NZ
UK
AU
IND
US
Core growth of 8.1 percent included about 3 percent from distributor inventory adjustments in the prior-year quarter and the timing of customer orders, so underlying growth is nearer 5 percent, simple arithmetic. Gross margin was 47.4 percent versus 45.4 percent, while adjusted gross margin …
Biohaven (NYSE:BHVN) licensed its MoDE pan-IgG degrader portfolio, BHV-1300, BHV-1310 and BHV-1320, to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries on October 8, 2026. It receives USD 80 million at signing, a USD 20 million milestone expected within about a year …
Merck (NYSE:MRK) and Daiichi Sankyo's decision to voluntarily withdraw the Biologics License Application for ifinatamab deruxtecan eliminates what several PDUFA calendar listings had flagged as a possible October 10 FDA decision date. A voluntary withdrawal differs meaningfully from an FDA rejection: it typically reflects …
According to In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx, it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. According to The company, safety was consistent …
Biohaven's license of BHV-1300 to Ono Pharma covering Japan, South Korea, Taiwan and ASEAN markets provides 80 million dollars in upfront cash plus a 20 million dollar near-term milestone, non-dilutiveCapitalthat extends the company's cash runway without requiring anEquityraise. Biohaven (NYSE:BHVN) retains rights to BHV-1300 …
According to In a release at 5:31 p.m. ET on October 7, 2026, Medtronic (NYSE:MDT), the final exchange ratio is 4.5939 MiniMed shares for each Medtronic ordinary share accepted. The offer expires at the end of October 9, 2026, at 12:00 midnight New York …
Neogen (NASDAQ:NEOG) released first quarter fiscal 2027 results for the quarter ended August 31, 2026 on October 6, 2026. Revenue of USD 222.8 million rose 6.5%, or 8.1% on a core basis. Domestic revenue was USD 110.1 million and international revenue was USD 112.7 …
Cooper Companies (NASDAQ:COO) traded at US$54.75 as of 8 October 2026, against an analyst consensus price target of US$69.57, an implied upside of approximately +27.1%.
DexCom, Inc. (NASDAQ:DXCM), a constituent of the S&P 500, traded at US$84.30 as of 8 October 2026, against an analyst consensus price target of US$90, an implied upside of approximately +6.8%.
Exelixis (NASDAQ:EXEL) traded at US$58.44 as of 8 October 2026, against an analyst consensus price target of US$50, an implied upside of approximately N/A.
Please wait processing your request...